This article was originally published in Start Up
TissueGen, a start-up spun out of the University of Texas, is developing a bioabsorbable stent that permits the delivery of hydrophilic, or water soluable, therapeutics. If successful the sent would open up the door for a whole new family of drugs to be delivered via a stent.
You may also be interested in...
Stent Recap: Turmoil in 2007--What's Ahead for Interventional Cardiology?
Although safety concerns about drug-eluting stents have been mitigated somewhat by recent reports of more positive clinical data, there is lingering unease and confusion in the cardiology community about when, how, and in whom to use these devices. There is also a growing wave of healthy skepticism about the way stent trials are designed and conducted, and whether evidence- based medicine is well served by the current process.
Amaranth Medical Inc.
With technology developed at Nanyang Technological University. Amaranth has entered into an increasingly competitive race involving start-ups with their eyes on a considerable prize-the creation of a vascular stent composed of biodegradable polymers.
Bioabsorbable Therapeutics Inc.
Bioabsorbable Therapeutics, a start-up built around technology developed at Rutgers University, expects to begin conducting clinical trials on its bioabsorbable stent. The company, which is constructing the stents with polymers that contain non-sterioidal anti-inflammatories, is targeting the coronary market.